A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control trea

Trial Details

NCT ID
NCT06465329
Phase
PHASE2
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cemiplimab
  • Platinum-based chemotherapy
  • REGN7075
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • Skokie, Illinois, United States|42.03336,-87.73339
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Farmington Hills, Michigan, United States|42.48531,-83.37716
  • Morristown, New Jersey, United States|40.79677,-74.48154

Key Eligibility Criteria

  • Histologically confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol
  • Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1
  • Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol
  • Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →